Participated · Series E · Jul 2024

Imperative Care is a commercial-stage medical technology company focused on advancing treatments for thromboembolic disease, including ischemic stroke and other vascular diseases caused by blood clots. Its commercially available product portfolio includes the Zoom Stroke System, the Symphony Thrombectomy System, and the Prodigy Thrombectomy System, which have been used in more than 78,000 procedures. The company is also developing the Telos endovascular robotic platform, currently in development and not approved for sale. Imperative Care said the $100 million convertible note financing will support commercialization of its existing stroke and vascular portfolios, next‑generation product development, and clinical evidence generation. The company is based in Campbell, Calif., and announced a new board appointment tied to the financing.

Participated · Series C · Sep 2022

JenaValve designs, develops and commercializes the Trilogy Heart Valve System, a TAVR platform intended to treat symptomatic, severe aortic regurgitation (AR) and aortic stenosis (AS) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021 and is positioned as a dual‑disease treatment device. The company has received FDA Breakthrough Device Designation for ALIGN-AR to facilitate review of a pivotal U.S. trial as part of a PMA filing. JenaValve intends to use its recent financing to complete an IDE/PMA study to obtain FDA approval for Trilogy in AR patients. Proceeds will also support real‑world data development in Europe and expansion of worldwide manufacturing capabilities. The company is led by CEO John Kilcoyne and operates locations in Irvine, CA, Leeds, U.K., and Munich, Germany. JenaValve Technology develops and manufactures differentiated transcatheter aortic valve replacement (TAVR) systems, including the Trilogy® TAVR system. The Trilogy system is intended to treat patients with severe symptomatic aortic regurgitation (AR) and aortic stenosis (AS). JenaValve is conducting the ALIGN-AR PMA clinical trial (IDE approved August 2021) and reports patient enrollment remains on track as it pursues U.S. FDA approval for the Trilogy Heart Valve System. The company said the capital from the new partnership will support the ALIGN-AR trial and accelerate expansion of its current commercial activities in Europe. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Existing backers include Bain Capital Life Sciences, Cormorant Asset Management, Andera Partners, Gimv, Legend Capital, NeoMed Management, RMM, Valiance Life Sciences, VI Partners and Peijia Medical. JenaValve develops the JenaValve Pericardial TAVR System, a self‑expanding nitinol stent with a porcine pericardial valve available in three sizes. The device is investigational and not available for sale in the U.S. or internationally. The company is conducting a global multicenter clinical program targeting severe aortic regurgitation (AR) and AR‑dominant mixed aortic valve disease in high‑risk surgical patients. JenaValve recently received Breakthrough Device designation from the U.S. FDA, which allows priority review of its Align Clinical Trial. Following completion of the Humanitarian Device Exemption (HDE) portion of the trial, enrollment will continue to support a Premarket Approval (PMA) submission under the Breakthrough program. The company also anticipates filing for CE mark approval for both aortic stenosis and aortic regurgitation in the second half of 2020. JenaValve Technology develops, manufactures and markets next-generation transcatheter aortic valve repair (TAVR) systems to treat patients with aortic valve disease. Its Transapical TAVR system (JenaValve valve plus Cathlete PLUS delivery) has CE Mark approval for aortic stenosis and the unique indication to treat aortic valve insufficiency. The company currently markets this product in Europe and selected markets worldwide and has operating locations in Munich, Germany and Irvine, California. JenaValve completed a $26.5 million Series C expansion financing to fund further growth in the global TAVR market. Proceeds will support key clinical studies required to gain European regulatory approval and to complete a U.S. feasibility study for a new aortic valve and transfemoral delivery system. The financing is positioned to help JenaValve advance its product pipeline and execute regulatory and clinical plans. JenaValve Technology develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems, including a CE‑marked transapical TAVI system currently sold in Europe and other markets. Its JenaValve prosthesis pairs a porcine bioprosthesis with a Nitinol self‑expanding stent and features a “3‑feeler element” for accurate positioning plus a JenaClip anchoring mechanism; the valve is retrievable and repositionable and implanted on the beating heart. The company’s transfemoral TAVI system entered a first‑in‑man clinical study at the end of 2013 and was anticipated to be commercially available in 2015. JenaValve positions its devices as second‑generation TAVI products aimed at easing implantation and reducing pacemaker implantation and paravalvular leakage. Financially, the company expanded its Series C by $10 million, bringing the round total to $72.5 million. JenaValve is a U.S. corporation with primary operations in Munich and was founded by cardiologists Prof. Hans R. Figulla and Prof. Markus Ferrari.

Led · Equity · Jul 2022

Syapse combines clinical expertise with smart technologies to transform data into evidence and experience in collaboration with a network of partners. The company is led by CEO Ken Tarkoff and is based in San Francisco and New York. Its core offering includes a Learning Health Network that partners with community health systems to support precision medicine strategies aimed at improving clinical outcomes, reducing costs, and enhancing patient experience. Syapse has also added life sciences partnerships with established biopharmaceutical companies. The company raised $35M in Growth funding and intends to use the funds to expand its focus on providing real-world insights to partners and assist them in improving outcomes for people with cancer. Syapse provides real-world evidence (RWE) and actionable treatment insights through its Syapse Learning Health Network to improve outcomes for people with cancer. The platform standardizes and normalizes de-identified clinical and molecular data across participating healthcare providers to support clinical decisions and research. Syapse has expanded partnerships with community health systems and life sciences companies and has collaborated with the FDA to address urgent public health challenges, including COVID-19. The company positions its network to drive precision medicine strategies that aim to improve clinical outcomes, reduce costs, and enhance patient experience. The announced financing is intended to expand partnering opportunities with life sciences, health systems, regulators, and molecular labs to deliver more real-world insights. Syapse works with leading health systems, life sciences companies, and regulators to accelerate the creation and use of real-world evidence to improve cancer patient outcomes. The company provides insights from real-world data through a portfolio of products that support research and product development, clinical trial patient matching, regulatory filings, and monitoring of commercially approved products. Syapse integrates clinical, molecular, and outcomes data to support large‑scale precision medicine programs at health systems. Its Syapse Learning Health Network is described in the press release as one of the world’s largest networks dedicated to improving outcomes in cancer care through precision medicine. The company recently presented collaborative research with the FDA Office of Clinical Pharmacology and Advocate Aurora Health on pneumonitis incidence at the AACR annual meeting, illustrating its RWE capabilities. Proceeds from the announced financing are intended to accelerate the creation and use of real‑world evidence in oncology and support Syapse’s ongoing collaborations and product development. Syapse develops an oncology software platform and the Syapse Data Sharing Network to enable physicians to view treatments and outcomes for patients across the country and apply that information to improve care. Led by CEO Ken Tarkoff and based in San Francisco, the company sells its platform to large health systems and lists customers including Intermountain Healthcare, Providence St. Joseph Health, Henry Ford Health System, Aurora Health Care, Catholic Health Initiatives and Dignity Health. Syapse recently raised $30m in Series D financing. The company intends to use the funds to expand operations and bring its solutions to more providers and their cancer patients. Its core product focuses on enabling consistent precision-medicine practice across large health systems by connecting treatment and outcome data. The Data Sharing Network is positioned as a clinical-data tool to inform treatment decisions across participating institutions. Syapse provides cloud-based precision medicine software to academic and community health systems to support widespread adoption of precision oncology. The platform integrates clinical, genomic, and other molecular data from medical records, labs, and pharmacies to create a longitudinal patient profile. It offers guidance on diagnostic and therapeutic strategy based on clinical best practices and supports implementation of treatment decisions while coordinating care across geographically dispersed teams. The software also measures patient outcomes to learn what works and improve best practices. Led by CEO Glenn Winokur and based in Palo Alto, Syapse intends to use new funding to expand adoption of its software in community health systems. The company completed the first close of a Series C financing as reported in December 2016.

Participated · Equity · Mar 2022

DNAnexus provides a cloud-based biomedical data analysis platform that enables researchers and life sciences companies to analyze genomic, transcriptomic, proteomic, metabolomic, and clinical datasets together. The company powers large-scale initiatives — it built and supports the UK Biobank Research Analysis Platform and exclusively partnered with the FDA to power precisionFDA. DNAnexus reports more than 12,000 platform users across 48 countries, stores over 65 petabytes of data, and says its stored data has grown 70% per year since 2015. Its customer base includes seven of the top 10 pharmaceutical companies and eight of the top 10 diagnostics companies. The company will use new funding to accelerate its product roadmap, advance its core genomics and multi-omics platform, expand internationally, and support integration of new AI and machine-learning technologies to drive precision medicine. DNAnexus offers an enterprise-grade, cloud-native informatics platform that simplifies complex data analysis, clinical data management, and insights at population scale. The DNAnexus Platform combines genomics, multi-omics, and real-world data with clinical datasets to support diagnostics, drug discovery, and cross-institutional collaboration. Customers run 10 million core processing hours per month and now store 28 petabytes of data, a dataset that has grown roughly 70% per year over the past four years. Its customer base spans government, biopharmaceutical, clinical diagnostics, healthcare, and academic research across 33 countries and includes eight of the top 10 clinical diagnostics companies and seven of the top 10 pharmaceutical companies. The platform supports some of the largest human genome sequencing projects and powers FDA’s precisionFDA platform. DNAnexus reports continued customer growth during the COVID-19 pandemic as organizations adopted its virtual cloud workspace. The company says the financing will advance its global expansion and further development of its data science and scaling capabilities. DNAnexus provides a secure, scalable platform for managing and analyzing genomics and other biomedical data. Its Apollo platform enables multi-omics and clinical data exploration, analysis, and discovery across the DNAnexus global network. The company operates in 33 countries, serving thousands of researchers across biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia. DNAnexus supports major projects including NIH’s All of Us, St. Jude Cloud, AstraZeneca’s 2‑million genome initiative, and the Regeneron‑Geisinger collaboration. The firm offers cloud-based solutions for research, clinical diagnostics, and clinical trials and emphasizes cross-institutional collaboration on large biomedical datasets. The recent financing is positioned to support further development of translational research solutions and continued growth in genomics. DNAnexus provides a secure, scalable cloud platform that enables enterprises and research organizations to manage, analyze and share large genomic and biomedical datasets. The company offers products including the DNAnexus Platform and the recently launched Mosaic Microbiome Platform, and has an early access program for Google Brain’s DeepVariant technology. It is developing and preparing to deploy a Translational Informatics Suite aimed at pharmaceutical and research customers. DNAnexus serves thousands of researchers across biopharma, clinical diagnostics, sequencing services, government and research consortia, and operates globally across North America, Europe, Asia‑Pacific (including China), South America and Africa. The company has announced collaborations with AstraZeneca’s Centre for Genomics Research and Rady Children’s Institute for Genomic Medicine. Recent financing will support expansion in the clinical trials market and continued product development and deployment. DNAnexus provides an enterprise PaaS that centralizes management, analysis, and sharing of DNA sequence data for labs and large organizations. The platform supplies secure, compliant cloud infrastructure that supports unlimited scaling of computational and storage resources and meets HIPAA, CLIA, and international regulatory requirements. It serves as a hub for collaboration, tool sharing, and access to reference genotypic and phenotypic datasets. Through projects with Stanford University and Baylor College of Medicine, DNAnexus processed over 17,000 genomes and generated more than 500 terabytes of genomic data, making those datasets available for follow-on analysis. The company reports rapid customer adoption and plans to expand capacity to support growing commercial and academic lab usage. DNAnexus has closed a $15 million Series C to accelerate commercialization of its enterprise platform.

Participated · Series B · Nov 2021

Geneoscopy leverages a proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform to develop diagnostic tests for gastrointestinal diseases. Its lead product, ColoSense, is an FDA-approved at-home, stool-based colorectal cancer screening test for average-risk individuals over age 45. The company pairs its RNA isolation platform with Bio-Rad’s Droplet Digital PCR (ddPCR) technology to achieve high sensitivity and specificity. Geneoscopy plans to launch and commercialize ColoSense and is working with Labcorp to provide broad availability so providers can order the test within screening programs. The firm is also investing in an innovative pipeline of diagnostic tests for inflammatory bowel disease, including tools for treatment selection and therapy monitoring. The recent financing is positioned to support commercialization, regulatory milestones, and continued product development. Geneoscopy is a St. Louis, MO–based life sciences company focused on developing diagnostic tests for gastrointestinal health. Its lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. The device was awarded Breakthrough Device Designation from the US FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Preliminary trials suggest the diagnostic can detect these lesions at a higher rate than existing noninvasive screening tests. The company intends to use recent funding to support the U.S. CRC-PREVENT pivotal trial, scale commercial infrastructure, and expand its diagnostic product pipeline. Andrew Barnell is the company's CEO. Geneoscopy is a life sciences company focused on developing diagnostic tests for gastrointestinal (GI) health. Its lead product is a colorectal cancer (CRC) screening test that quantifies eukaryotic RNA isolated from epithelial cells in stool to detect CRC and advanced adenomas. The company announced an oversubscribed $6.9 million Series A and plans to use the proceeds to advance the CRC screening test. The financing was led by Cultivation Capital and NT Investments, with Lightchain Capital LLC as a significant investor. Following the round, Bobby W. Sandage, Jr., Najeeb Thomas, and Drew Dennison are joining Geneoscopy’s board of directors. Geneoscopy highlights that stool-derived eukaryotic RNA biomarkers are highly sensitive for both cancer and precancerous lesions, and it intends to pursue other applications of its platform technology.